Treatment of myelodysplastic syndromes: Practical tools for effective management

Clinical Journal of Oncology Nursing

Volumn 16, Issue 3 SUPPL., 2012, Pages 23-35

  Kurtin, Sandra E ^a,b   Demakos, Erin P ^c   Hayden, Janet ^d   Boglione, Claudia ^e  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

AGED; ARTICLE; CASE REPORT; DISEASE MANAGEMENT; HUMAN; MALE; METHODOLOGY; MYELODYSPLASTIC SYNDROME; NURSING; ONCOLOGY NURSING; PATIENT CARE PLANNING; PROGNOSIS; RISK ASSESSMENT;

AGED; ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYELODYSPLASTIC SYNDROMES; ONCOLOGIC NURSING; PATIENT CARE PLANNING; PROGNOSIS; RISK ASSESSMENT;

EID: 84863820594     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/12.CJON.S1.23-35     Document Type: Article

References (43)

1. Bejar, R., Levine, R., & Ebert, B.L. (2011). Unraveling the molecular pathophysiology of myelodysplastic syndromes. Journal of Clinical Oncology, 29, 504-515. doi:10.1200/JCO.2010.31.1175
2. Catenacci, D.V., & Schiller, G.J. (2005). Myelodysplastic syndromes: A comprehensive review. Blood Reviews, 19, 301-319. doi:10.1016/j.blre.2005.01. 004 (Pubitemid 41571931)
3. Celgene Corporation. (2009). Revlimid® (lenalidomide) [Prescribing information]. Retrieved from http://www.revlimid.com/docs/Revlimid-Full-PI.pdf
4. Celgene Corporation. (2011). Vidaza® (azacitidine) [Prescribing information]. Retrieved from http://www.vidaza.com/pdf/PI-FlNAL.pdf
5. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., ⋯ Kantarjian, H. (2006). Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419-425. doi:10.1182/blood-2005-10-4149 (Pubitemid 44061337)
6. Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G.J., Mittelman, M.,⋯ Hellstrom-Lindberg, E. (2009). RBC transfusion independence and safety profile of lenalidomide 5 or 10 mg in patients with low-or int-1 risk MDS with del5q: Results from a randomized phase II trial (MDS-004) [Abstract 944]. Blood, 114, 390.
7. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A.,⋯ International Vidaza High-Risk MDS Survival Study Group. (2009). Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncology, 10, 223-232. doi:10.1016/S1470-2045 (09)70003-8
8. Garcia-Manero, G. (2010). Prognosis of myelodysplastic syndromes. Hematology/The American Society of Hematology Education Program, 330-337. doi:10.1182/asheducation-2010.1.330
9. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., ⋯ Bennett, J. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088. (Pubitemid 27132124)
10. Greenberg, P., Tuechler, H., Schanz, J., Sole, F., Bennett, J.M., Garcia-Manero, G., ⋯ Haase, D. (2011). Revised International Prognostic Scoring System (IPSS-R), developed by the International Working Group for Prognosis in MDS (IWG-PM) [Abstract 14]. Leukemia Research, 35(Suppl. 1), S6.
11. Harvey, R.D. (2010). Myelodysplastic syndromes and the role of iron overload. American Journal of Health-System Pharmacy, 67(7, Suppl. 2), S3-S9. doi:10.2146/ajhp090645
12. Hershko, C. (2005). Treating iron overload: The state of the art. Seminars in Hematology, 42(2, Suppl. 1), S2-S4. (Pubitemid 40410476)
13. Jadersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Gohring, G., ⋯ Mufti, G.J. (2011). TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. Journal of Clinical Oncology, 29, 1971-1979. doi:10.1200/JCO.2010.31.8576
14. Jansen, A.J., Essink-Bot, M.L., Beckers, E.A., Hop, W.C., Schipperus, M.R., & Van Rhenen, D.J. (2003). Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. British Journal of Haematology, 121, 270-274. (Pubitemid 36560593)
15. Kantarjian, H., Issa, J.P., Rosenfeld, C.S., Bennett, J.M., Albitar, M., DiPersio, J., ⋯ Saba, H. (2006). Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer, 106, 1794-1803. doi:10.1002/cncr.21792
16. Komrokji, R.S., Sekeres, M.A., & List, A.F. (2011). Management of lower-risk myelodysplastic syndromes: The art and evidence. Current Hematologic Malignancy Reports, 6, 145-153. doi:10.1007/s11899-011-0086-x
17. Komrokji, R.S., Zhang, L., & Bennett, J.M. (2010). Myelodysplastic syndromes classification and risk stratification. Hematology/Oncology Clinics of North America, 24, 443-457. doi:10.1016/j.hoc.2010.02.004
18. Kurtin, S. (2010). Risk analysis in the treatment of hematological malignancies in the elderly. Journal of the Advanced Practitioner in Oncology, 1, 119-129.
19. Kurtin, S. (2011a). Current approaches to the diagnosis and management of myelodysplastic syndromes. Journal of the Advanced Practitioner in Oncology, 2(Suppl. 2), 7-18.
20. Kurtin, S. (2011b). Leukemia and myelodysplastic syndromes. In C.H. Yarbro, D. Wujcik, & B.H. Gobel (Eds.), Cancer nursing: Principles and practice (7th ed., pp. 1369-1398). Sudbury, MA: Jones and Bartlett.
21. Kurtin, S., & Demakos, W. (2011). Disease burden associated with quality of life in myelodysplastic syndromes: Findings from a Web-based survey [Abstract 354]. Leukemia Research, 35(Suppl. 1), S142.
22. Kurtin, S.E. (2007). Myelodysplastic syndromes: Diagnosis, treatment planning, and clinical management. Oncology (Williston Park), 21(11, Suppl. Nurse Ed.), 41-48.
23. Kurtin, S.E., & Demakos, E.P. (2010). An update on the treatment of myelodysplastic syndromes [Online exclusive]. Clinical Journal of Oncology Nursing, 14, E24-E39. doi:10.1188/10.CJON.E24-E39
24. Kurtin, S.E., & List, A.F. (2009). Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide. Clinical Lymphoma and Myeloma, 9, E10-E13. doi:10.3816/CLM.2009.n.053
25. List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Myelodysplastic Syndrome-003 Study Investigators. (2006). Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine, 355, 1456-1465. doi:10.1056/NEJMoa061292 (Pubitemid 44511560)
26. List, A., Kurtin, S., Roe, D.J., Buresh, A., Mahadevan, D., Fuchs, D.,⋯ Zeldis, J.B. (2005). Efficacy of lenalidomide in myelodysplastic syndromes. New England Journal of Medicine, 352, 549-557. (Pubitemid 40204668)
27. Lubbert, M., Suciu, S., Baila, L., Ruter, B.H., Platzbecker, U., Giagounidis, A., ⋯ Wijermans, P.W. (2011). Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. Journal of Clinical Oncology, 29, 1987-1996. doi:10.1200/JCO.2010.30.9245
28. Malcovati, L., Porta, M.G., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E.,⋯ Cazzola, M. (2005). Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria. Journal of Clinical Oncology, 23, 7594-7603. (Pubitemid 46291823)
29. Naqvi, K., Garcia-Manero, G., Sardesai, S., Oh, J., Vigil, C.E., Pierce, S.,⋯ Suarez-Almazor, M.E. (2011). Association of comorbidities with overall survival in myelodysplastic syndrome: Development of a prognostic model. Journal of Clinical Oncology, 29, 2240-2246. doi:10.1200/JCO.2010.31.3353
30. National Comprehensive Cancer Network. (2011a). NCCN Clinical Practice Guidelines in Oncology: Acute myeloid leukemia [v2.2011]. Retrieved from http://www.nccn.org/professionals/physician-gls/PDF/aml.pdf
31. National Comprehensive Cancer Network. (2011b). NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic syndromes [v2.2011]. Retrieved from http://www.nccn.org/professionals/physician-gIs/PDF/mds.pdf
32. Oliva, E., Dimitrov, B., D Angelo, A., Martino, B., Perna, A., & Nobile, F. (2001). QOL-E: A new tool for the assessment of quality of life in myelodysplastic syndrome. Blood, 98, 427a. (Pubitemid 33787888)
33. Price, E.A., Mehra, R., Holmes, T.H., & Schrier, S.L. (2011). Anemia in older persons: Etiology and evaluation. Blood Cells, Molecules and Diseases, 46, 159-165. doi:10.1016/j.bcmd.2010.11.004
34. Pullarkat, V. (2009). Objectives of iron chelation therapy in myelodysplastic syndromes: More than meets the eye? Blood, 114, 5251-5255. doi:10.1182/blood-2009-07-234062
35. Raza, A., Reeves, J.A., Feldman, E.J., Dewald, G.W., Bennett, J.M., Deeg, H.J., ⋯ List, A.F. (2008). Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood, 111, 86-93.
36. Sekeres, M.A., Maciejewski, J.P., Giagounidis, A.A., Wride, K., Knight, R., Raza, A., & List, A.F. (2008). Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology, 26, 5943-5949. doi:10.1200/JCO.2007.15.5770
37. Sekeres, M.A., Maciejewski, J.P., List, A.F., Steensma, D.P., Artz, A., Swern, A.S., ⋯ Stone, R. (2011). Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: Results from an Internet-based survey. Oncologist, 16, 904-911. doi:10.1634/ theoncologist.2010-0199
38. Silverman, L.R., Fenaux, P., Mufti, G.J., Santini, V., Hellstrom-Lindberg, E., Gattermann, N., ⋯ Seymour, J.F. (2011). Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer, 117, 2697-2702. doi:10.1002/cncr.25774
39. Spiriti, M.A., Latagliata, R., Niscola, P., Cortelezzi, A., Francesconi, M., Ferrari, D., ⋯ Petti, M.C. (2005). Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Annals of Hematology, 84, 167-176. doi:10.1007/s00277-004-0961-9 (Pubitemid 40260326)
40. Steensma, D.P., Baer, M.R., Slack, J.L., Buckstein, R., Godley, L.A., Garcia-Manero, G., Kantarjian, H. (2009). Multicenter study of decitabine administered daily for 5 days every four weeks to adults with myelodysplastic syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) trial. Journal of Clinical Oncology, 27, 3842-3848. doi:10.1200/JCO.2008.19.6550
41. Steensma, D.P., & Stone, R.M. (2010). Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematology/Oncology Clinics of North America, 24, 389-406. doi:10.1016/j.hoc. 2010.02.012
42. SuperGen, Inc. (2010). Dacogen® (decitabine) [Prescribing information]. Retrieved from http://us.eisai.com/pdf-files/Dacogen-PI.pdf
43. Verburgh, E., Achten, R., Maes, B., Hagemeijer, A., Boogaerts, M., De Wolf-Peeters, C., & Verhoef, G. (2003). Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. Journal of Clinical Oncology, 21, 273-282. (Pubitemid 46606156)